Clinical Trials ArenaOriginal article
MapLight Therapeutics stock crashes on Phase II schizophrenia data
Phase 2MixedNegative
AI Analysis
Summary
MapLight Therapeutics' Phase 2 schizophrenia trial showed mixed results, with the twice-daily dosing regimen meeting the primary endpoint while the daily dose failed to do so, leading to a stock decline.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Twice-daily dose met primary endpoint; daily dose did not meet primary endpoint
Importance:6/10
Sentiment:
-0.70
Phase 2schizophreniaclinical trialmixed resultsstock decline
Read the original article
Published by Clinical Trials Arena on July 28, 2026 2:06 PM